Thus, GNF362 may be a viable inhibitor of ITPKB, and should be tested in dopaminergic models of PD as to whether it can be neuroprotective, and in finding wider applications to the neurodegenerative field. This evidence concerns the gene ITPKB and Parkinson disease.